Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dominic Kelly

Showing results (31-40 of 53) with videos related to

Pageof 6
Sort By:
Emerging Microbes & Infections|August 13, 2025
Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccinationAapo Knuutila, Niina Ahvenainen, Alex-Mikael Barkoff, et al.
Journal of Cardiac Failure|November 11, 2008
C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarctionDominic Kelly, Iain B Squire, Sohail Q Khan, et al.
The Lancet. Rheumatology|October 21, 2020
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLHAkhila Kavirayani, James E G Charlesworth, Shelley Segal, et al.
The New England Journal of Medicine|July 3, 2024
Normalization of C1 Inhibitor in a Patient with Hereditary AngioedemaNicholas E Peters, Dylan J Mac Lochlainn, Fatima Dhalla, et al.
International Journal of Cardiology|July 28, 2012
Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?Onkar S Dhillon, Hafid K Narayan, Sohail Q Khan, et al.
The American Journal of Cardiology|August 10, 2010
Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarctionDominic Kelly, Iain B Squire, Sohail Q Khan, et al.
Pediatric Blood & Cancer|June 11, 2021
Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill childrenJames E G Charlesworth, Shaun Wilson, Amrana Qureshi, et al.
Clinical Science (London, England : 1979)|January 28, 2009
N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndromeSohail Q Khan, Hafid Narayan, Kelvin H Ng, et al.
Circulation. Cardiovascular Genetics|April 3, 2013
MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarctionYvan Devaux, Melanie Vausort, Gerry P McCann, et al.
Journal of the American College of Cardiology|May 10, 2008
Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) studySohail Q Khan, Onkar Dhillon, Dominic Kelly, et al.
Pageof 6

Showing results (31-40 of 53) with videos related to

Sort By:
Pageof 6
Emerging Microbes & Infections|August 13, 2025
Prior immunological memory to pertussis toxin affects the avidity development of anti-PT IgG antibodies after acellular pertussis booster vaccinationAapo Knuutila, Niina Ahvenainen, Alex-Mikael Barkoff, et al.
Journal of Cardiac Failure|November 11, 2008
C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarctionDominic Kelly, Iain B Squire, Sohail Q Khan, et al.
The Lancet. Rheumatology|October 21, 2020
The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLHAkhila Kavirayani, James E G Charlesworth, Shelley Segal, et al.
The New England Journal of Medicine|July 3, 2024
Normalization of C1 Inhibitor in a Patient with Hereditary AngioedemaNicholas E Peters, Dylan J Mac Lochlainn, Fatima Dhalla, et al.
International Journal of Cardiology|July 28, 2012
Pre-discharge risk stratification in unselected STEMI: is there a role for ST2 or its natural ligand IL-33 when compared with contemporary risk markers?Onkar S Dhillon, Hafid K Narayan, Sohail Q Khan, et al.
The American Journal of Cardiology|August 10, 2010
Usefulness of plasma tissue inhibitors of metalloproteinases as markers of prognosis after acute myocardial infarctionDominic Kelly, Iain B Squire, Sohail Q Khan, et al.
Pediatric Blood & Cancer|June 11, 2021
Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill childrenJames E G Charlesworth, Shaun Wilson, Amrana Qureshi, et al.
Clinical Science (London, England : 1979)|January 28, 2009
N-terminal pro-B-type natriuretic peptide complements the GRACE risk score in predicting early and late mortality following acute coronary syndromeSohail Q Khan, Hafid Narayan, Kelvin H Ng, et al.
Circulation. Cardiovascular Genetics|April 3, 2013
MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarctionYvan Devaux, Melanie Vausort, Gerry P McCann, et al.
Journal of the American College of Cardiology|May 10, 2008
Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) studySohail Q Khan, Onkar Dhillon, Dominic Kelly, et al.
Pageof 6